Klaria Pharma Holding AB (publ.) (KLAR.ST)

SEK 0.29

(-8.63%)

Operating Expenses Summary of Klaria Pharma Holding AB (publ.)

Klaria Pharma Holding AB (publ.)'s latest annual operating expenses in 2023 was 14.88 Million SEK , down -47.48% from previous year.
Klaria Pharma Holding AB (publ.)'s latest quarterly operating expenses in 2024 Q2 was 1.97 Million SEK , down -29.69% from previous quarter.
Klaria Pharma Holding AB (publ.) reported a annual operating expenses of 61.3 Million SEK in annual operating expenses 2022, down -24.29% from previous year.
Klaria Pharma Holding AB (publ.) reported a annual operating expenses of 80.97 Million SEK in annual operating expenses 2021, up 65.58% from previous year.
Klaria Pharma Holding AB (publ.) reported a quarterly operating expenses of 2.81 Million SEK for 2024 Q1, down -59.46% from previous quarter.
Klaria Pharma Holding AB (publ.) reported a quarterly operating expenses of 9.53 Million SEK for 2023 Q2, down -12.41% from previous quarter.

Annual Operating Expenses Chart of Klaria Pharma Holding AB (publ.) (2023 - 2014)

Historical Annual Operating Expenses of Klaria Pharma Holding AB (publ.) (2023 - 2014)

Year	Operating Expenses	Operating Expenses Growth
2023	14.88 Million SEK	-47.48%
2022	61.3 Million SEK	-24.29%
2021	80.97 Million SEK	65.58%
2020	48.9 Million SEK	93.06%
2019	25.33 Million SEK	-7.26%
2018	27.31 Million SEK	87.77%
2017	14.54 Million SEK	0.49%
2016	14.47 Million SEK	158.85%
2015	5.59 Million SEK	1757.38%
2014	301.07 Thousand SEK	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	1.97 Million SEK	-29.69%
2024 Q1	2.81 Million SEK	-59.46%
2023 Q2	9.53 Million SEK	-12.41%
2023 Q3	10.25 Million SEK	7.59%
2023 FY	14.88 Million SEK	-75.72%
2023 Q4	6.93 Million SEK	-32.35%
2023 Q1	10.88 Million SEK	-9.25%
2022 Q2	13.39 Million SEK	-30.01%
2022 Q1	19.14 Million SEK	-72.68%
2022 Q4	11.99 Million SEK	-8.58%
2022 FY	61.3 Million SEK	-24.29%
2022 Q3	13.11 Million SEK	-2.11%
2021 Q3	14.51 Million SEK	4.4%
2021 Q2	13.9 Million SEK	179.34%
2021 Q4	70.07 Million SEK	382.68%
2021 FY	80.97 Million SEK	65.58%
2021 Q1	-17.52 Million SEK	-205.33%
2020 Q3	12.65 Million SEK	35.19%
2020 FY	48.9 Million SEK	93.06%
2020 Q4	16.63 Million SEK	31.51%
2020 Q2	9.35 Million SEK	-8.73%
2020 Q1	10.25 Million SEK	134.81%
2019 Q3	7.08 Million SEK	-11.13%
2019 Q2	7.97 Million SEK	34.96%
2019 Q1	5.9 Million SEK	-61.27%
2019 FY	25.33 Million SEK	-7.26%
2019 Q4	4.36 Million SEK	-38.36%
2018 Q1	3.84 Million SEK	-7.77%
2018 FY	27.31 Million SEK	87.77%
2018 Q3	3.72 Million SEK	-17.1%
2018 Q2	4.49 Million SEK	16.86%
2018 Q4	15.25 Million SEK	309.59%
2017 Q2	3.46 Million SEK	9.29%
2017 Q4	4.16 Million SEK	11.59%
2017 Q3	3.73 Million SEK	7.67%
2017 FY	14.54 Million SEK	0.49%
2017 Q1	3.17 Million SEK	5.13%
2016 Q3	3.16 Million SEK	-28.85%
2016 FY	14.47 Million SEK	158.85%
2016 Q4	3.01 Million SEK	-4.64%
2016 Q1	3.84 Million SEK	5.0%
2016 Q2	4.45 Million SEK	15.89%
2015 Q1	233.5 Thousand SEK	0.0%
2015 Q2	467 Thousand SEK	100.0%
2015 Q3	1.5 Million SEK	222.91%
2015 Q4	3.65 Million SEK	142.51%
2015 FY	5.59 Million SEK	1757.38%
2014 FY	301.07 Thousand SEK	0.0%

Peer Operating Expenses Comparison of Klaria Pharma Holding AB (publ.)

Name	Operating Expenses	Operating Expenses Difference
AcuCort AB	13.24 Million SEK	-12.341%
AlzeCure Pharma AB (publ)	38.26 Million SEK	61.1%
BioGaia AB (publ)	507.08 Million SEK	97.065%
Enzymatica AB (publ)	79.92 Million SEK	81.378%
Enorama Pharma AB (publ)	38.22 Million SEK	61.063%
Gabather AB (publ)	9.47 Million SEK	-57.104%
Moberg Pharma AB (publ)	27.46 Million SEK	45.803%
Nanexa AB (publ)	135.78 Million SEK	89.038%
Newbury Pharmaceuticals AB (publ)	30.11 Million SEK	50.57%
ODI Pharma AB	-5.00 SEK	297680100.0%
Orexo AB (publ)	659.4 Million SEK	97.743%
Probi AB (publ)	208.93 Million SEK	92.876%
Swedencare AB (publ)	1.12 Billion SEK	98.68%
Swedish Orphan Biovitrum AB (publ)	9.39 Billion SEK	99.842%
Toleranzia AB	6.97 Million SEK	-113.483%
Vivesto AB	355.71 Million SEK	95.816%